Non-invasive therapy ANEUVO's ExaStim is a non-invasive neuromodulation platform with CE Mark and FDA 510(k) clearance, indicating a regulatory readiness to pursue pilots or trials in markets where approvals exist. Sales opportunities include partnering with medical centers and rehabilitation clinics focused on spinal cord injury and disabling conditions.

Strategic funding momentum Recent Series C funding of 22M signals investor confidence and potential for accelerated commercial expansion, clinical studies, and new market entry. Leverage this credibility to approach hospital systems, researchers, and private clinics for large-scale adoption.

Award and recognition Taiwan National Innovation Award in the International Startup track highlights international validation. This can be used to open discussions with distributors, government-linked healthcare programs, and regional partners in Asia seeking innovative medical device solutions.

Market positioning Active focus on spinal cord injury and disabling diseases with a platform architecture suitable for neuromodulation therapies. Potential opportunities include collaboration with SCI centers, rehabilitation networks, and device distributors seeking complementary technologies to expand their neuromodulation portfolios.

Targeted partnerships Limited current commercial reach outside CE/FDA regions; opportunities exist to engage strategic distributors and contract research organizations in North America and Europe to accelerate clinical outreach, payer discussions, and staged market rollout for ExaStim.